NYSE:DGX • US74834L1008
The current stock price of DGX is 212.76 USD. In the past month the price increased by 16.31%. In the past year, price increased by 24.03%.
ChartMill assigns a technical rating of 10 / 10 to DGX. When comparing the yearly performance of all stocks, DGX is one of the better performing stocks in the market, outperforming 76.61% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to DGX. While DGX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months DGX reported a non-GAAP Earnings per Share(EPS) of 9.85. The EPS increased by 9.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.88% | ||
| ROA | 5.95% | ||
| ROE | 13.27% | ||
| Debt/Equity | 0.71 |
24 analysts have analysed DGX and the average price target is 202.57 USD. This implies a price decrease of -4.79% is expected in the next year compared to the current price of 212.76.
For the next year, analysts expect an EPS growth of 6.73% and a revenue growth 3.68% for DGX
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.69 | 97.772B | ||
| CI | THE CIGNA GROUP | 9.37 | 77.65B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 97.51 | 24.095B | ||
| LH | LABCORP HOLDINGS INC | 16.11 | 24.032B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.861B | ||
| DVA | DAVITA INC | 11.1 | 9.89B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 29.47 | 7.225B | ||
| CHE | CHEMED CORP | 18.13 | 6.555B | ||
| OPCH | OPTION CARE HEALTH INC | 18.06 | 5.503B |
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. The company is headquartered in Secaucus, New Jersey and currently employs 45,000 full-time employees. The firm provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. The company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. The company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The company also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
QUEST DIAGNOSTICS INC
500 Plaza Drive
Secaucus NEW JERSEY 07094 US
CEO: Stephen H. Rusckowski
Employees: 45000
Phone: 13026587581
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. The company is headquartered in Secaucus, New Jersey and currently employs 45,000 full-time employees. The firm provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. The company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. The company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The company also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
The current stock price of DGX is 212.76 USD. The price increased by 1.64% in the last trading session.
QUEST DIAGNOSTICS INC (DGX) has a dividend yield of 1.64%. The yearly dividend amount is currently 2.98.
DGX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
QUEST DIAGNOSTICS INC (DGX) operates in the Health Care sector and the Health Care Providers & Services industry.
The Revenue of QUEST DIAGNOSTICS INC (DGX) is expected to grow by 3.68% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
QUEST DIAGNOSTICS INC (DGX) has a market capitalization of 23.67B USD. This makes DGX a Large Cap stock.